| Autor: |
MANABE, Ryo, ANDO, Koichi, KUSUMOTO, Sojiro, TANAKA, Akihiko, YAMAOKA, Toshimitsu, OHMORI, Tohru, OHNISHI, Tsukasa, SAGARA, Hironori |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Zdroj: |
The Showa University journal of medical sciences. 30(2):309-315 |
| ISSN: |
0915-6380 |
| Popis: |
The safety and efficacy profiles of alectinib versus crizotinib for patients with previously untreated anaplastic lymphoma kinase （ALK）-positive advanced non-small cell lung cancer still remains to be elucidated. We compared the overall efficacies of alectinib and crizotinib for previously untreated ALK-positive advanced non-small cell lung cancer through a meta-analysis of randomized controlled trials. The primary outcome was progression-free survival （PFS）. Pooled estimates were calculated as hazard ratios with 95％ confidence intervals. Two studies on alectinib met the inclusion criteria for this meta-analysis. The hazard ratio （95％ confidence interval） of alectinib for PFS, relative to crizotinib, was 0.41 （0.28-0.60）, demonstrating a superior overall efficacy of alectinib over crizotinib, in terms of PFS. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
